PDX bank from urothelial cancer to guide precision medicine.

ABSTRACT: We developed preclinical PDX models, recapitulating the molecular heterogeneity of MIBCs and UTUC, which will represent an essential tool in therapy development. Pharmacological characterization of the PDXs suggested that upper urinary tract and bladder cancers (UCC/ SCC) with similar molecular characteristics could benefit from the same treatments, and showed a benefit for combined FGFR/EGFR inhibition in FGFR3-mutant PDXs, compared to FGFR inhibition alone.

ORGANISM(S): Homo sapiens

PROVIDER: GSE181962 | GEO | 2022/08/31

REPOSITORIES: GEO